Author + information
- Received November 21, 1989
- Revision received February 7, 1990
- Accepted March 7, 1990
- Published online August 1, 1990.
- Richard N. Fogoros, MD, FACC∗,
- James J. Elson, MD, PhD,
- Christopher A. Bonnet, MD,
- Susan B. Fiedler, RN and
- John A. Burkholder, MD
- ↵∗Address for reprints: Richard N. Fogoros, MD, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, Pennsylvania 15212.
The ability of the automatic implantable cardioverter-defibrillator to prolong overall survival, particularly in patients with significantly depressed cardiac function, has not been well documented. Of 119 patients who received the implantable defibrillator in this institution, 40 had a left ventricular ejection fraction < 30% (Group A) and 79 had an ejection fraction ≥ 30% (Group B). For each group, cumulative survival was compared with the projected survival if the implantable defibrillator had not been used. Projected survival was based on the assumption that the first appropriate shock would have resulted in death without the defibrillator.
For Group A, the 3 year cumulative survival rate was 67 ± 12% versus a projected survival rate of 6 ± 15% (p < 0.001). For Group B, the 3 year cumulative survival rate was 96 ± 3% versus a projected survival rate of 46 ± 8% (p < 0.001). Both the cumulative and projected survival rates for patients in Group A were significantly worse than for patients in Group B (p < 0.01). The projected survival rates for both Groups A and B were comparable with the observed survival rate in similar patients treated without the implantable definbrillator.
In summary, the implantable cardioverter-defibrillator significantly prolonged overall survival, even in patients with poor cardiac function. The technique of estimating projected survival appears to allow a realistic estimate of the reduction in mortality achieved by the defibrillator.
- Received November 21, 1989.
- Revision received February 7, 1990.
- Accepted March 7, 1990.